These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34497852)

  • 1. Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial.
    Jiang LL; Zhang P; Liu BL; Yan RN; Ye L; Ma JH; Li FF
    Biomed Res Int; 2021; 2021():6618257. PubMed ID: 34497852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A; Shigiyama F; Kitazawa T; Okada Y; Ichijo T; Higa M; Hiyoshi T; Inoue I; Iso K; Yoshii H; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2020 Jan; 19(1):1. PubMed ID: 31910850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Dapaglifozin and Liraglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: a 24-week, Open, Double-centered, Head to Head Trial.
    Jiang J; Lin L; Chen P
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1366-1374. PubMed ID: 32875989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
    Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
    Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
    Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
    Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study.
    Shin Y; Choi H; Lim S
    Diabetes Res Clin Pract; 2021 May; 175():108843. PubMed ID: 33933498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study.
    Lee SH; Min KW; Lee BW; Jeong IK; Yoo SJ; Kwon HS; Choi YH; Yoon KH
    Diabetes Metab J; 2021 May; 45(3):339-348. PubMed ID: 32602273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial.
    Sposito AC; Breder I; Soares AAS; Kimura-Medorima ST; Munhoz DB; Cintra RMR; Bonilha I; Oliveira DC; Breder JC; Cavalcante P; Moreira C; Moura FA; de Lima-Junior JC; do Carmo HRP; Barreto J; Nadruz W; Carvalho LSF; Quinaglia T;
    Cardiovasc Diabetol; 2021 Mar; 20(1):74. PubMed ID: 33771149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
    J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
    Li FF; Gao G; Li Q; Zhu HH; Su XF; Wu JD; Ye L; Ma JH
    J Diabetes Res; 2016; 2016():5347262. PubMed ID: 27738639
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
    Li FF; Jiang LL; Yan RN; Zhu HH; Zhou PH; Zhang DF; Su XF; Wu JD; Ye L; Ma JH
    Medicine (Baltimore); 2016 Oct; 95(43):e5229. PubMed ID: 27787387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Daniele G; Tura A; Brocchi A; Saba A; Campi B; Sancho-Bornez V; Dardano A; Del Prato S
    Diabetes Care; 2024 Jul; 47(7):1131-1139. PubMed ID: 38652656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
    Sun Y; Yan D; Hao Z; Cui L; Li G
    Med Sci Monit; 2020 Apr; 26():e921891. PubMed ID: 32240122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes.
    Li FF; Liu BL; Yin GP; Yan RN; Zhang DF; Wu JD; Ye L; Su XF; Ma JH
    Sci Rep; 2018 Jun; 8(1):9713. PubMed ID: 29946148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.